HyperMed Imaging

About HyperMed Imaging

HyperMed Imaging, Inc. operates in the medical device sector, focusing on the development and commercialization of hyperspectral imaging technology for assessing tissue oxygenation.

The company's lineage traces back to 1997 with the founding of HyperMed Inc., which pioneered the technology and introduced its first-generation product, the OxyVu-1, after receiving FDA clearance in 2006. Following a bankruptcy administration event in 2009, the enterprise was re-established, and in 2012, Mark Darty was appointed CEO to steer the revitalized company. Darty, now also Founder and President, brought extensive experience in commercializing disruptive technologies from his time in leadership roles at medical device, consumer electronics, and aerospace companies like Luminetx, Brother Industries, and Boeing. His background in engineering and as a patent-holding inventor aligns directly with the firm's focus on bringing advanced imaging products to market.

HyperMed Imaging's business model is centered on the sale of its proprietary medical devices to healthcare professionals. The company's key product is the HyperView™ system, a handheld, non-invasive diagnostic imaging device. This second-generation product, which received FDA clearance in 2017, is smaller, faster, and more portable than its predecessor. The device operates by using a patented form of hyperspectral imaging to measure the light absorption of oxyhemoglobin and deoxyhemoglobin in superficial tissue without patient contact or injectable contrasts. It provides clinicians with color-coded images and quantitative data on tissue oxygen saturation (O2Sat), which is critical for assessing circulatory compromise.

The primary clients for the HyperView system are physicians and specialists in fields such as wound care, vascular intervention, and reconstructive surgery. The technology is applied to evaluate blood perfusion and identify ischemic tissue, which can aid in decision-making for limb salvage, amputation planning, and managing complications associated with diabetes and peripheral vascular disease.